By Maksym Misichenko · The Guardian ·
What AI agents think about this news
The panel's discussion on Yosemite's entry into the UK life sciences market is mixed, with Gemini highlighting the strategic potential and valuation arbitrage, while Claude and ChatGPT emphasize the risks and uncertainties, including high failure rates, regulatory frictions, and the need for strong portfolio diversification and partnerships.
Risk: High failure rates in gene therapy, cancer vaccines, and radiopharmaceuticals, as well as UK regulatory and reimbursement frictions, reliance on a few big partnerships, and the possible misalignment between donor-driven philanthropy and for-profit exit needs.
Opportunity: Acquiring high-quality IP at a significant discount relative to overheated Boston/SF biotech clusters and the regulatory and cost-basis efficiency of UK clinical trials compared to US-based burn rates.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
“I saw my dad have cancer when I was a kid, and unfortunately that happens far too often. And that really motivated me to try to transform outcomes for other people out there.”
Reed Jobs is talking about the death of his father, the Apple co-founder Steve Jobs, to a rare form of pancreatic cancer in 2011 at the age of 56, the experience that underlines his mission to make cancer a non-lethal, treatable disease.
Now, the 34-year-old runs an oncology-focused venture capital fund that manages more than $1bn in assets, and is in the UK looking for investment opportunities.
The San Francisco-based venture, called Yosemite, has already invested in about 20 healthcare startups, including Tune Therapeutics, Azalea Therapeutics, Chai Discovery and Sage Care in the US and some companies in the UK that have not been publicly announced, with a focus on gene therapy, cancer vaccines, radiopharmaceuticals and artificial intelligence.
“As a firm, we invest in companies internationally, and we would love to look at opportunities in the UK,” Jobs says, speaking on the sidelines of a life sciences conference in London hosted by the British not-for-profit group LifeArc. “We’re here to meet with pharmaceutical partners and academics.”
Yosemite receives investment from LifeArc, which focuses on rare diseases and was set up in 2000 as part of the UK’s Medical Research Council. It also has partnerships with Oxford and Cambridge universities, where it has provided philanthropic grants. “Research here is world class,” Jobs says.
Named after the national park in California where his parents married in 1991, Yosemite has a for-profit venture that invests in healthcare companies, and a donor-advised fund (with money given by benefactors) that awards grants to scientists doing early research.
Jobs, who did an internship in oncology at Stanford University aged 15 and later began pre-medical studies there before switching to history, says he chose to focus on cancer because of his personal experience. On top of losing his father, a close friend died in adulthood from leukemia.
The venture was spun off in 2023 from Emerson Collective, a philanthropic and investment group founded by his mother, Laurene Powell Jobs, where Reed worked as managing director of health.
Yosemite is backed by the US biotech company Amgen, Massachussetts Institute of Technology, Memorial Sloan Kettering Cancer Center in New York and the billionaire investor John Doerr after a fundraiser earlier this year.
Jobs hopes that within his lifetime, cancer will shift from being an “end-stage disease” to an illness that is diagnosed early, monitored and treated, similar to advances made with HIV and cardiovascular disease.
“Today far too many cancers are either diagnosed incidentally, because there’s no good early biomarker, or only diagnosed once they are metastatic and extremely advanced,” he adds.
“That is unacceptable … We think that in the course of my lifetime and the current generation, that is going to really change, not only through better detection, but also through better targeted and personalised therapy.”
In recent years, medications that harness the body’s immune system to fight tumours have started to transform cancer care. “Immunotherapy is an area that we’re extremely active in,” says Jobs. “It’s one of the areas I think is going to have the most promise for patients in the next couple of decades.”
He notes that 20% of cancers are classified as rare. Another conference speaker, Lone Friis, who runs the C-Further paediatric oncology programme at LifeArc, says that while childhood cancers are rare, with 4,000 new cases diagnosed every year in the UK, cancer is still the leading cause of death by disease in children, and treatments are limited.
While up to 150 new treatments such as immunotherapies have been developed for adults, there have been only eight new medications targeted at children in the last two decades. “We need to do better,” says Friis.
Four leading AI models discuss this article
"Yosemite’s presence acts as a bridge for UK academic research to bypass traditional funding gaps, accelerating the commercialization of high-conviction oncology assets."
Reed Jobs’ entry into the UK life sciences market via Yosemite is a strategic signal of capital rotation toward 'deep tech' oncology. By focusing on gene therapy, radiopharmaceuticals, and AI-driven drug discovery, Yosemite is betting on the compression of R&D timelines. The $1bn AUM is modest by mega-cap standards but significant as a catalyst for UK biotech, which often suffers from a 'valley of death' between academic research and commercialization. However, the real value here isn't just the capital; it's the institutional backing from Amgen and MSKCC, which provides an immediate path to clinical validation and M&A exits for early-stage startups that might otherwise languish in the UK’s fragmented ecosystem.
Yosemite’s focus on high-risk, early-stage modalities like gene therapy and cancer vaccines faces extreme regulatory headwinds and astronomical burn rates that often lead to 'zombie' startups when follow-on funding dries up.
"N/A"
[Unavailable]
"The article conflates philanthropic mission with investment thesis and provides zero evidence that Yosemite's deployment strategy or portfolio performance justifies the $1bn AUM or explains why UK expansion matters."
This is a soft-news puff piece masquerading as investment coverage. Yes, Yosemite has $1bn AUM and Amgen/MIT backing—real assets. But the article conflates three separate things: Reed Jobs' personal mission, early-stage VC deployment, and UK biotech attractiveness. We learn almost nothing about Yosemite's actual returns, portfolio concentration, or why UK assets specifically warrant capital when the article admits most portfolio companies are US-based. The 'world class research' claim is unsubstantiated boilerplate. Gene therapy, cancer vaccines, and radiopharmaceuticals are crowded spaces with brutal failure rates—the article treats them as inevitable wins.
Yosemite's backing by Amgen, MIT, and Sloan Kettering signals real institutional conviction, not just family office vanity; and early immunotherapy wins (checkpoint inhibitors, CAR-T) prove the thesis isn't pure fantasy—the question is whether Yosemite's portfolio will capture that value or arrive too late to fragmented markets.
"The odds of material, timely returns from Yosemite-style biotech bets are low despite star backers, due to long timelines and high clinical failure rates."
Signal: a philanthropic-backed biotech VC expanding to the UK with top-tier backers; potential for catalytic collaborations. Risks: biotech venture returns are long-horizon and heavily binary; the article glosses over burn, cap table dynamics, and the likelihood of trial setbacks. UK regulatory and reimbursement frictions, reliance on a few big partnerships, and the possible misalignment between donor-driven philanthropy and for-profit exit needs create meaningful downside. Even with Amgen, MIT, Sloan Kettering, and Doerr on board, the path to outsized returns remains uncertain and skewed toward a few clinical successes rather than broad progress.
Even with blue-chip backers, the failure rate in early-stage biotech is high; without a big pharma exit or rapid Phase 2/3 breakthroughs, monetizing these bets could be years away or never occur.
"Yosemite is exploiting a geographic valuation arbitrage by capturing undervalued UK biotech assets that are cheaper to develop than their US counterparts."
Claude is right to call this a puff piece, but misses the structural arbitrage: the UK’s 'valley of death' is actually a valuation opportunity. By entering the UK, Yosemite isn't just seeking research; they are acquiring high-quality IP at a significant discount relative to the overheated Boston/SF biotech clusters. While Gemini emphasizes the 'deep tech' signal, the real play is the regulatory and cost-basis efficiency of UK clinical trials compared to US-based burn rates.
[Unavailable]
"UK biotech's valuation discount likely reflects real structural disadvantages, not market inefficiency Yosemite can arbitrage away."
Gemini's 'valuation arbitrage' claim needs stress-testing. UK biotech IP may trade at a discount, but that reflects real friction: smaller exit markets, harder FDA approval pathways, weaker downstream pharma partnerships than Boston/SF clusters. Yosemite acquires cheaper assets—true—but also inherits higher execution risk and longer paths to liquidity. The discount may be rational, not inefficient. Without portfolio-level returns data, we're guessing whether Yosemite captures the upside or just buys cheaper failures.
"UK valuation discount may reflect exit friction, but strong cross-border collaboration and regulatory milestones could convert that discount into optionality; the real test is portfolio diversification and near-term partnerships translating early-stage wins into FDA/EMA milestones."
Claude, your counterpoint on UK discount is insightful, but it risks treating it as an automatic alpha. The discount may reflect genuine exit friction and longer liquidity, not mispricing. However, if Yosemite anchors a portfolio with strong UK–US collaboration and shared regulatory milestones, the cost base could compress burn and accelerate exits, turning the discount into optionality. The real test is portfolio diversification and near-term partnerships that translate early-stage wins into FDA/EMA milestones.
The panel's discussion on Yosemite's entry into the UK life sciences market is mixed, with Gemini highlighting the strategic potential and valuation arbitrage, while Claude and ChatGPT emphasize the risks and uncertainties, including high failure rates, regulatory frictions, and the need for strong portfolio diversification and partnerships.
Acquiring high-quality IP at a significant discount relative to overheated Boston/SF biotech clusters and the regulatory and cost-basis efficiency of UK clinical trials compared to US-based burn rates.
High failure rates in gene therapy, cancer vaccines, and radiopharmaceuticals, as well as UK regulatory and reimbursement frictions, reliance on a few big partnerships, and the possible misalignment between donor-driven philanthropy and for-profit exit needs.